癌症病史与分娩严重并发症相关
Cancer History Tied to Severe Maternal Morbidity During Childbirth
一项横断面研究显示,过去癌症幸存者的分娩住院率增加,严重并发症发生率是无癌症女性的1.45倍,当前癌症患者则高达3.80倍。研究还指出,孕前评估和多学科团队转诊对癌症幸存者尤为重要。
— Deliveries among cancer survivors have increased in recent years
November 17, 2026 • 3 min read
- Hospital deliveries among past cancer survivors increased over an 8-year period, while deliveries among current cancer patients were relatively unchanged.
- Severe maternal morbidity was higher for past cancer survivors and current cancer patients compared with women without cancer.
- Most hospital deliveries (57.6%) for past cancer survivors were full term, while only 39.6% were full term for current cancer patients.
More cancer survivors are giving birth, and severe maternal morbidity was increased at delivery for both past survivors and current cancer patients, a cross-sectional study in the U.S. showed.
From 2016 to 2023, hospital deliveries increased from 30.1 to 45.6 per 10,000 for past cancer survivors (average annual percentage change [AAPC] 6.3%), while hospital deliveries for current cancer patients were relatively unchanged (7.0 to 7.4 per 10,000 deliveries, AAPC 0.2%), reported Koji Matsuo, MD, PhD, of the University of Southern California in Los Angeles, and colleagues in JAMA Network Open.
Compared with a severe maternal morbidity rate of 6.8 per 1,000 hospital deliveries for people without cancer, this rate was 11.9 per 1,000 deliveries for past cancer survivors (adjusted incidence rate ratio [IRR] 1.45, 95% CI 1.37-1.53) and 48.2 per 1,000 deliveries for current cancer patients (adjusted IRR 3.80, 95% CI 3.58-4.04).
Of note, the inpatient maternal mortality rate during the admission for hospital delivery was 14-fold higher for current cancer patients compared with those without cancer (273.0 vs 7.0 per 100,000 hospital deliveries; adjusted IRR 14.24, 95% CI 10.87-18.66).
"As cancer care and outcomes have improved and fertility preservation and assisted reproductive technology have become more widely available, pregnancy after cancer is an important issue in survivorship care for reproductive-aged individuals, including adolescent and young adult cancer survivors," wrote Matsuo and colleagues. "The increase in delivery hospitalizations among past cancer survivors in the U.S. may partly reflect these changes."
"These findings support the importance of preconception evaluation for cancer survivors and early referral to tertiary care centers with multidisciplinary teams, as currently recommended by multiple organizations," they added.
This study used national hospital discharge data from the Healthcare Cost and Utilization Project's National Inpatient Sample, which approximates a sample of 20% of discharges from participating hospitals across 48 states and the District of Columbia.
Among 28,360,443 hospital deliveries, 0.4% were among past cancer survivors, less than 0.1% were among current cancer patients, and 99.5% were among women without a cancer diagnosis. Median age at delivery was 33, 32, and 29 years across the three groups, respectively.
Among past cancer survivors, thyroid cancer (22.3%) was the most frequent type of cancer diagnosis, followed by cutaneous melanoma (15.7%), breast cancer (11.7%), lymphoma (10.8%), uterine cervical cancer (6.6%), leukemia (4.2%), and ovarian cancer (3.6%).
The study's primary outcome was severe maternal morbidity at the time of delivery, with morbidity indicators restricted to those with a case-fatality rate of 1% or higher after an event. The most common were cardiac arrest or ventricular fibrillation, conversion of cardiac rhythm, heart failure or arrest during surgery or a procedure, and amniotic fluid embolism.
Rates of severe maternal morbidity at delivery varied by cancer type, with greater associations seen among survivors of leukemia and lymphoma, and more modest associations with breast, cervical, and thyroid cancers.
Most hospital deliveries (57.6%) for past cancer survivors were full term, while only 39.6% were full term for current cancer patients.
Matsuo and colleagues acknowledged that the study had several limitations. For instance, they pointed out that unmeasured confounding factors were possible since they did not have access to information on cancer stage, histologic type, familial cancer syndrome, treatment history, duration of remission, residual organ dysfunction, or detailed disease status.
来源:MedPage Today · medpagetoday.com